Open Access
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +15 more
Reads0
Chats0
TLDR
The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued development and standardization of methodologies for biomarkers and has provided an increased depth and breadth of data available to qualified researchers.About:
The article was published on 2017-04-01 and is currently open access. It has received 169 citations till now. The article focuses on the topics: Alzheimer's Disease Neuroimaging Initiative & Biomarker (medicine).read more
Citations
More filters
Journal ArticleDOI
Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer’s disease
Panagiotis Alexopoulos,Panagiotis Alexopoulos,Lena-Sophie Gleixner,Lukas Werle,Lukas Werle,Felix Buhl,Nathalie Thierjung,Evangelia Giourou,Simone Maria Kagerbauer,Philippos Gourzis,Hubert Kübler,Timo Grimmer,Igor Yakushev,Jan Martin,Alexander Kurz,Robert Perneczky +15 more
TL;DR: In this paper, the authors reported that plasma levels of soluble amyloid precursor protein β (sAPPβ) were significantly lower in patients with symptomatic AD (21 with mild cognitive impairment due to AD and 44 with AD dementia) with AD-typical cerebral hypometabolic pattern compared with 27 cognitively healthy elderly individuals without preclinical AD.
Journal ArticleDOI
Editorial: Multimodal and Longitudinal Bioimaging Methods for Characterizing the Progressive Course of Dementia
Journal ArticleDOI
The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.
Laila Abdullah,Fiona Crawford,Fiona Crawford,Magda Tsolaki,Anne Börjesson-Hanson,Marcel G. M. Olde Rikkert,Florence Pasquier,Anders Wallin,Sean Kennelly,Sean Kennelly,Ghania Ait-Ghezala,Daniel Paris,Suzanne Hendrix,Kaj Blennow,Kaj Blennow,Brian A. Lawlor,Michael Mullan,Michael Mullan +17 more
TL;DR: It is suggested that baseline AD severity influenced the treatment outcome in the NILVAD trial and that future clinical trials of nilvadipine should be restricted to mild and very mild AD patients.
Journal ArticleDOI
Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease
TL;DR: The present role of genetic and biochemical biomarkers in Parkinson Disease is reviewed and areas where the use of biomarkers may benefit clinical trial planning, as well as clinical care through the application of a "precision medicine" approach, in the near term are highlighted.
Journal ArticleDOI
Finding specificity in structural brain alterations through Bayesian reverse inference
Franco Cauda,Andrea Nani,Donato Liloia,Jordi Manuello,Enrico Premi,Sergio Duca,Peter T. Fox,Tommaso Costa +7 more
TL;DR: A new analytical instrument capable of innovating the methodological approach to the investigation of brain pathology is put forward, which was employed, as a proof of concept, on voxel‐based morphometry data of schizophrenia and Alzheimer's disease.
References
More filters
Journal ArticleDOI
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
John Hardy,Dennis J. Selkoe +1 more
TL;DR: It has been more than 10 years since it was first proposed that the neurodegeneration in Alzheimer's disease (AD) may be caused by deposition of amyloid β-peptide in plaques in brain tissue and the rest of the disease process is proposed to result from an imbalance between Aβ production and Aβ clearance.
Journal ArticleDOI
Complex brain networks: graph theoretical analysis of structural and functional systems
Edward T. Bullmore,Olaf Sporns +1 more
TL;DR: This article reviews studies investigating complex brain networks in diverse experimental modalities and provides an accessible introduction to the basic principles of graph theory and highlights the technical challenges and key questions to be addressed by future developments in this rapidly moving field.
Journal ArticleDOI
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling,Paul S. Aisen,Laurel A. Beckett,David A. Bennett,Suzanne Craft,Anne M. Fagan,Takeshi Iwatsubo,Clifford R. Jack,Jeffrey Kaye,Thomas J. Montine,Denise C. Park,Eric M. Reiman,Christopher C. Rowe,Eric Siemers,Yaakov Stern,Kristine Yaffe,Maria C. Carrillo,Bill Thies,Marcelle Morrison-Bogorad,Molly V. Wagster,Creighton H. Phelps +20 more
TL;DR: A conceptual framework and operational research criteria are proposed, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies and it is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD.
Journal Article
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,C. R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +17 more
Journal ArticleDOI
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack,David S. Knopman,William J. Jagust,Leslie M. Shaw,Paul S. Aisen,Michael W. Weiner,Ronald C. Petersen,John Q. Trojanowski +7 more
TL;DR: This work proposes a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegnerative biomarker become abnormal later, and correlate with clinical symptom severity.
Related Papers (5)
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Jesse M. Cedarbaum,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Johan Luthman,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Li Shen,Adam J. Schwarz,Arthur W. Toga,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +19 more
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.
Dallas P. Veitch,Michael W. Weiner,Paul S. Aisen,Laurel A. Beckett,Charles DeCarli,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Susan M. Landau,John C. Morris,Ozioma C. Okonkwo,Richard J. Perrin,Ronald C. Petersen,Monica Rivera-Mindt,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,Duygu Tosun,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +20 more